GondolaBio logo

GondolaBio Funding & Investors

GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.

gondolabio.com

Total Amount Raised: $300,000,000

GondolaBio Funding Rounds

  • Series Unknown

    $300,000,000

    Series Unknown Investors

    Patient Square Capital
    Viking Global Investors
    Cormorant Asset Management
    Sequoia Capital
    Frazier Life Sciences
    Aisling Capital
Funding info provided by Diffbot.